Keyphrases
Abiraterone
19%
American Society of Hematology
23%
Anticoagulation
35%
Apixaban
17%
Assessment Development
10%
Bleeding
14%
Cancer-associated Thrombosis
9%
Cancer-associated Venous Thromboembolism
13%
Chemotherapy
12%
Comorbid Diseases
10%
Comparative Effectiveness
10%
Confidence Interval
24%
Coronavirus Disease (COVID)
11%
COVID-19
13%
Critically Ill Patients
9%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
Direct Oral Anticoagulants
26%
Dose Reduction
12%
Enzalutamide
19%
Evaluation Assessment
10%
Frailty
9%
Grading of Recommendations
10%
Hematological Malignancies
10%
Hemostasis
16%
High Risk
10%
Hospitalization
9%
In Cancer
15%
Living Guidelines
19%
Major Bleeding
10%
Malignancy
17%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
14%
Multiple Myeloma
71%
Overall Survival
11%
Patients with Cancer
16%
Patients with COVID-19
20%
Patients with Obesity
9%
Reduced Dose
9%
Retrospective Cohort Study
14%
Risk Prediction Model
8%
Statins
9%
Thromboprophylaxis
33%
Thrombosis
22%
United States Veterans
23%
US Veterans
8%
Venous Thromboembolism
82%
Venous Thromboembolism Risk
12%
Venous Thromboembolism Treatment
10%
Venus
9%
Veterans Health Administration
9%
Warfarin
12%
Medicine and Dentistry
Acute Disease
6%
Anticoagulation
36%
Antithrombotic
5%
Apixaban
14%
Bleeding
19%
Blood Stasis
16%
Cancer
17%
Cancer Treatment
11%
Chemotherapy
15%
CHOP
9%
Clinician
20%
COVID-19
38%
Critical Illness
8%
Dexamethasone
5%
Diffuse Large B-Cell Lymphoma
14%
Direct Oral Anticoagulant
20%
Disease
8%
Drug Dose Reduction
10%
Hazard Ratio
8%
Health Care
5%
Health Outcomes
5%
Hematologic Malignancy
10%
Hematology
23%
Immunomodulatory Drug
5%
International Classification of Diseases
5%
Lenalidomide
6%
Low Molecular Weight Heparin
6%
Major Bleeding
10%
Malignant Neoplasm
23%
Multiple Myeloma
49%
Odds Ratio
11%
Oncology
5%
Overall Survival
6%
Pancreas Adenocarcinoma
5%
Pancreas Cancer
9%
Phlebothrombosis
5%
Placebo
5%
Randomized Clinical Trial
5%
Randomized Controlled Trial
6%
Retrospective Cohort Study
10%
Risk Stratification
6%
Rivaroxaban
6%
Sarcopenia
9%
Secondary Prevention
5%
Thrombocytopenia
9%
Thromboprophylaxis
33%
Thrombosis
37%
Venous Thromboembolism
100%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone
19%
Apixaban
11%
Bleeding
19%
Chemotherapy
20%
Cohort Study
14%
Dexamethasone
5%
Diffuse Large B Cell Lymphoma
15%
Direct Oral Anticoagulant
15%
Disease
14%
Enzalutamide
19%
Frailty
9%
Hematologic Malignancy
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
9%
Infection
5%
Lenalidomide
6%
Malignant Neoplasm
20%
Multiple Myeloma
49%
Overall Survival
7%
Prostate Cancer
14%
Thrombosis
25%
Venous Thromboembolism
57%
Warfarin
14%